Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001523 | Mental Disorders NIH | 0.20 |
| D013313 | Stress Disorders, Post-Traumatic NIH | 0.17 |
| D004194 | Disease NIH | 0.16 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Currently, there is no specific treatment or vaccine for SARS-CoV-2 available, some drugs are being investigated as treatment, but the effect is unknown. A strategy and other method used before, in coronavirus pandemic (SARS-CoV in 2003 and MERS-CoV in 2012), was the use of immune (convalescent) plasma. Passive administration of antibodies through convalescent plasma transfusion may offer the only short-term strategy available to confer immediate immunity and being a relative immediately resource available for treat COVID-19 disease. This research proposes the passive administration of antibodies through the transfusion of convalescent plasma, in patients with severe COVID-19 disease.
Description: Change in ordinal Scale for Clinical Improvement (WHO). The progression disease, its the change in the severity score; a bigger number to the obtained after randomization
Measure: Disease progression Time: Up to 30 days later from study entryDescription: Side effects associated with the administration of convalescent plasma
Measure: Side effects Time: Up to 30 days later from study entryDescription: Any cause of death
Measure: Mortality Time: Up to 30 days later from study entryDescription: Change in partial pressure of arterial Oxygen to Fraction of inspired Oxygen ratio (PaO2/FiO2)
Measure: Respiratory improvement Time: 10 daysDescription: Change in oxygen saturation levels
Measure: Clinical improvement Time: 10 daysDescription: Transfusion reactions during transfusion.
Measure: Acute adverse events (AAE) Time: After receiving intervention, an average time one hour, until 24 hours after administration.Description: Change in pro-inflammatory biomarkers (D dimer μg/l)
Measure: Inflammatory biomarkers (D dimer) Time: 10 daysDescription: Change in pro-inflammatory biomarkers ( Ferritin μg/L )
Measure: Inflammatory biomarkers (Ferritin) Time: 10 daysDescription: Change in pro-inflammatory biomarkers, C-reactive protein ( CPR mg/L )
Measure: Inflammatory biomarkers (CPR) Time: 10 daysDescription: Change in pro-inflammatory biomarkers, lactate dehydrogenase ( LDH UI/L)
Measure: Inflammatory biomarkers (LDH) Time: 10 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports